IL317818A - Oligonucleotides for reduction of pd-l1 expression - Google Patents
Oligonucleotides for reduction of pd-l1 expressionInfo
- Publication number
- IL317818A IL317818A IL317818A IL31781824A IL317818A IL 317818 A IL317818 A IL 317818A IL 317818 A IL317818 A IL 317818A IL 31781824 A IL31781824 A IL 31781824A IL 317818 A IL317818 A IL 317818A
- Authority
- IL
- Israel
- Prior art keywords
- antisense oligonucleotide
- conjugate
- pharmaceutical composition
- oligonucleotide conjugate
- moiety
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
Claims (28)
1. 1
2. CLAIMS 1. An antisense oligonucleotide which comprises a contiguous nucleotide sequence of 10 to nucleotides in length capable of reducing the expression of PD-L1, wherein the contiguous nucleotide sequence is at least 90% complementary to a PD-L1 target nucleic acid, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid, wherein the sub-sequence is selected from the group consisting of positions 5467-12107, 15317-15720, 15317-18083, 15317-19511, 9812-9859, 15690-15735, 371-3068, 7300-7333, 8028-8072, 11787-11873 and 18881-19494 on SEQ ID NO: 1. 2. An antisense oligonucleotide which comprises a contiguous nucleotide sequence of 10 to nucleotides in length with at least 90% complementarity to a PD-L1 target nucleic acid, and at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 466, 640, 6, 8, 9, 13, 41, 42, 58, 77, 92, 111, 128, 151, 164, 166, 169, 171, 222, 233, 245, 246, 250, 251, 252, 256, 272, 273, 287, 292, 303, 314, 318, 320, 324, 336, 342, 343, 344, 345, 346, 349, 359, 360, 374, 408, 409, 415, 417, 424, 429, 430, 458, 464, 474, 490, 493, 512, 519, 529, 533, 534, 547, 566, 567, 578, 582, 601, 619, 620, 636, 637, 638, 645, 650, 651, 652, 653, 658, 659, 660, 665, 678, 679, 680, 682, 683, 684, 687, 694, 706, 716, 728, 733, 734, and 735.
3. The antisense oligonucleotide of claim 2, wherein the contiguous nucleotide sequence has 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 466, 640, 6, 8, 9, 13, 41, 42, 58, 77, 92, 111, 128, 151, 164, 166, 169, 171, 222, 233, 245, 246, 250, 251, 252, 256, 272, 273, 287, 292, 303, 314, 318, 320, 324, 336, 342, 343, 344, 345, 346, 349, 359, 360, 374, 408, 409, 415, 417, 424, 429, 430, 458, 464, 474, 490, 493, 512, 519, 529, 533, 534, 547, 566, 567, 578, 582, 601, 619, 620, 636, 637, 638, 645, 650, 651, 652, 653, 658, 659, 660, 665, 678, 679, 680, 682, 683, 684, 687, 694, 706, 716, 728, 733, 734, and 735.
4. An antisense oligonucleotide conjugate comprising the oligonucleotide of any one of claims 1 to 3 and a conjugate moiety covalently attached to said oligonucleotide.
5. The antisense oligonucleotide conjugate of claim 4, wherein a linker is present between the oligonucleotide and the conjugate moiety. 1
6. The antisense oligonucleotide conjugate of claim 4 or claim 5, wherein the conjugate moiety is an asialoglycoprotein receptor targeting moiety.
7. The antisense oligonucleotide conjugate of claim 6, wherein the asialoglycoprotein receptor targeting moiety is a tri-valent N-acetylgalactosamine (GalNAc) moiety.
8. The antisense oligonucleotide conjugate of any one of claims 5 to 7, wherein the linker is a physiologically labile linker.
9. The antisense oligonucleotide conjugate of claim 8, wherein the physiologically labile linker is a nuclease susceptible linker.
10. The antisense oligonucleotide conjugate of claim 8 or claim 9 wherein the physiologically labile linker comprises a cytidine-adenosine dinucleotide.
11. The antisense oligonucleotide conjugate of claim 4 wherein a linker is present between the oligonucleotide and the conjugate moiety; further wherein the conjugate moiety comprises an asialoglycoprotein receptor targeting moiety that is a tri-valent N-acetylgalactosamine (GalNAc) moiety; wherein the linker is a physiologically labile linker; further wherein the physiologically labile linker comprises a cytidine-adenosine dinucleotide.
12. A pharmaceutical composition comprising the antisense oligonucleotide of any one of claims 1 to 3, or the antisense oligonucleotide conjugate of any one of claims 4 to 11 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
13. The pharmaceutical composition according to claim 12 wherein the pharmaceutically acceptable diluent is sterile phosphate buffered saline.
14. The pharmaceutical composition according to claim 12 or claim 13 wherein the pharmaceutically acceptable salt is sodium.
15. The pharmaceutical composition according to claim 12 or claim 13 wherein the pharmaceutically acceptable salt is potassium.
16. An in vivo or in vitro method for modulating PD-L1 expression in a target cell which is expressing PD-L1, said method comprising administering the antisense oligonucleotide of 1 any one of claims 1 to 3, the antisense oligonucleotide conjugate of any one of claims to 11, or the pharmaceutical composition of any one of claims 12 to 15 in an effective amount to said cell.
17. The antisense oligonucleotide of any one of claims 1 to 3, the antisense oligonucleotide conjugate of any one of claims 4 to 11, or the pharmaceutical composition of any one of claims 12 to 15 for use in restoration of immune response against a virus.
18. The antisense oligonucleotide, antisense oligonucleotide conjugate or pharmaceutical composition for use according to claim 17, wherein the virus is HBV.
19. The antisense oligonucleotide of any one of claims 1 to 3, the antisense oligonucleotide conjugate of any one of claims 4 to 11, or the pharmaceutical composition of any one of claims 12 to 15 for use in restoration of immune response against a parasite.
20. The antisense oligonucleotide, antisense oligonucleotide conjugate or pharmaceutical composition for use of any one of claims 17 to 19, wherein the restoration of the immune response is an increase in the liver of CD8+ T cells specific to one or more HBV antigens when compared to a control.
21. The antisense oligonucleotide of any one of claims 1 to 3, the antisense oligonucleotide conjugate of any one of claims 4 to 11, or the pharmaceutical composition of any one of claims 12 to 15 for use as a medicament.
22. The antisense oligonucleotide of any one of claims 1 to 3, the antisense oligonucleotide conjugate of any one of claims 4 to 11, or the pharmaceutical composition of any one of claims 12 to 15 for use in the treatment of HBV infection.
23. Use of the antisense oligonucleotide of any one of claims 1 to 3, the antisense oligonucleotide conjugate of any one of claims 4 to 11, or the pharmaceutical composition of any one of claims 12 to 15, for the preparation of a medicament for treatment of HBV infection.
24. A method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide of any one of claims to 3, the antisense oligonucleotide conjugate of any one of claims 4 to 11, or the 1 pharmaceutical composition of any one of claims 12 to 15 to a subject suffering from or susceptible to the disease.
25. A method for treating or preventing HBV infection comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide of any one of claims 1 to 3, the antisense oligonucleotide conjugate of any one of claims 4 to 11, or the pharmaceutical composition of any one of claims 12 to 15 to a subject suffering from or susceptible to HBV infection.
26. A pharmaceutically acceptable salt of the antisense oligonucleotide of any one of claims to 3, or the antisense oligonucleotide conjugate of any one of claims 4 to 11.
27. A pharmaceutically acceptable sodium salt of the antisense oligonucleotide of any one of claims 1 to 3, or the antisense oligonucleotide conjugate of any one of claims 4 to 11.
28. A pharmaceutically acceptable potassium salt of the antisense oligonucleotide of any one of claims 1 to 3, or the antisense oligonucleotide conjugate of any one of claims 4 to 11.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16160149 | 2016-03-14 | ||
| PCT/EP2017/055925 WO2017157899A1 (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides for reduction of pd-l1 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317818A true IL317818A (en) | 2025-02-01 |
Family
ID=58314191
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296483A IL296483B2 (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides for reduction of pd-l1 expression |
| IL303077A IL303077B2 (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides to reduce PD–L1 expression |
| IL317818A IL317818A (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides for reduction of pd-l1 expression |
| IL260759A IL260759B (en) | 2016-03-14 | 2018-07-24 | Oligonucleotides to reduce expression of pd-l1 |
| IL290294A IL290294B2 (en) | 2016-03-14 | 2022-02-01 | Oligonucleotides to reduce pd–l1 expression |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296483A IL296483B2 (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides for reduction of pd-l1 expression |
| IL303077A IL303077B2 (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides to reduce PD–L1 expression |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL260759A IL260759B (en) | 2016-03-14 | 2018-07-24 | Oligonucleotides to reduce expression of pd-l1 |
| IL290294A IL290294B2 (en) | 2016-03-14 | 2022-02-01 | Oligonucleotides to reduce pd–l1 expression |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US20170283496A1 (en) |
| EP (2) | EP3430141B1 (en) |
| JP (5) | JP6748219B2 (en) |
| KR (5) | KR102306797B1 (en) |
| CN (5) | CN108779465B (en) |
| AR (2) | AR108038A1 (en) |
| AU (4) | AU2017235278C1 (en) |
| CA (2) | CA3013683C (en) |
| CL (4) | CL2018002570A1 (en) |
| CO (1) | CO2018007761A2 (en) |
| CR (2) | CR20180432A (en) |
| DK (1) | DK3430141T3 (en) |
| ES (1) | ES2857702T3 (en) |
| HR (1) | HRP20210315T1 (en) |
| HU (1) | HUE053172T2 (en) |
| IL (5) | IL296483B2 (en) |
| LT (1) | LT3430141T (en) |
| MX (2) | MX2018010830A (en) |
| MY (1) | MY194912A (en) |
| PE (3) | PE20230157A1 (en) |
| PH (1) | PH12018501964A1 (en) |
| PL (1) | PL3430141T3 (en) |
| PT (1) | PT3430141T (en) |
| RS (1) | RS61528B1 (en) |
| RU (1) | RU2747822C2 (en) |
| SG (1) | SG11201807854SA (en) |
| SI (1) | SI3430141T1 (en) |
| TW (5) | TWI840950B (en) |
| UA (1) | UA127432C2 (en) |
| WO (1) | WO2017157899A1 (en) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0923225A2 (en) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | Phosphorus-modified nucleic acid synthesis method |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRECURSORS AND THEIR METHODS OF USE |
| DK2620428T3 (en) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetric help group |
| CN107365339A (en) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | Methods of Synthesizing Functionalized Nucleic Acids |
| DK2872147T3 (en) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | METHOD FOR PREPARATION OF CHIRAL OLIGONUCLEOTIDES |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| BR112018001232A2 (en) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 expressing hematopoietic stem cells and uses |
| CA3013683C (en) | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| US20220354888A1 (en) * | 2016-08-03 | 2022-11-10 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| KR102519171B1 (en) | 2016-10-07 | 2023-04-07 | 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 | A new approach to cancer treatment |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| KR20200030594A (en) * | 2017-10-16 | 2020-03-20 | 에프. 호프만-라 로슈 아게 | Nucleic acid molecule for reducing PAPD5 and PAPD7 mRNA to treat hepatitis B infection |
| EP3684377B1 (en) | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
| MY203356A (en) | 2018-01-12 | 2024-06-25 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2019140236A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| CN112513273A (en) | 2018-06-22 | 2021-03-16 | 豪夫迈·罗氏有限公司 | Oligonucleotides for modulating SCN9A expression |
| WO2020007772A1 (en) * | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting gbp-1 |
| WO2020011653A1 (en) * | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
| BR112021000538A2 (en) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | OLIGONUCLEOTIDS TO MODULATE RTEL1 EXPRESSION |
| WO2020081585A1 (en) * | 2018-10-15 | 2020-04-23 | The Brigham And Women's Hospital, Inc. | The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy |
| WO2020178258A1 (en) * | 2019-03-05 | 2020-09-10 | F. Hoffmann-La Roche Ag | Intracellular targeting of molecules |
| US20220177894A1 (en) | 2019-04-02 | 2022-06-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for immunotherapy |
| EP3959313A4 (en) * | 2019-04-26 | 2023-09-27 | Stoke Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING OF ALTERNATIVE INTRONS |
| CN114051531A (en) | 2019-05-03 | 2022-02-15 | 瑟卡尔纳制药有限公司 | PD-L1 antisense oligonucleotides for use in tumor therapy |
| WO2021122910A1 (en) * | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sbds inhibitors for treating hepatitis b virus infection |
| JP7634542B2 (en) * | 2019-12-19 | 2025-02-21 | エフ. ホフマン-ラ ロシュ アーゲー | Use of SEPT9 inhibitors for treating hepatitis B virus infection - Patents.com |
| WO2021123086A1 (en) * | 2019-12-20 | 2021-06-24 | F. Hoffmann-La Roche Ag | Enhanced oligonucleotides for inhibiting scn9a expression |
| EP4081217A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| WO2021173812A1 (en) * | 2020-02-28 | 2021-09-02 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| JP2023536999A (en) * | 2020-08-05 | 2023-08-30 | エフ. ホフマン-ラ ロシュ アーゲー | Oligonucleotide treatment of hepatitis B patients |
| CN114507663B (en) * | 2020-11-16 | 2026-07-17 | 浙江柏拉阿图医药科技有限公司 | Oligonucleotide and application thereof in resisting hepatitis B and hepatitis delta virus |
| TW202246500A (en) * | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | Enhanced oligonucleotides for inhibiting rtel1 expression |
| CN115216474B (en) * | 2021-04-15 | 2025-09-30 | 武汉大学 | Antisense oligonucleotides promoting PD-L1 exon 3 skipping and their applications |
| CN117836006A (en) * | 2021-08-04 | 2024-04-05 | 和博医药有限公司 | Ligand conjugates for delivery of therapeutically active agents |
| CN113789324B (en) * | 2021-08-17 | 2023-08-25 | 广东省大湾区华南理工大学聚集诱导发光高等研究院 | AIE probe, preparation method thereof and application thereof in fluorescent quantitative PCR (polymerase chain reaction) method |
| AU2022384619A1 (en) | 2021-11-11 | 2024-04-11 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| EP4551596A4 (en) * | 2022-07-06 | 2026-07-22 | Adverum Biotechnologies Inc | Compositions and methods for the treatment of achromopsia |
| TW202430637A (en) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3 targeting oligonucleotides and uses thereof |
| CN116597936A (en) * | 2023-01-30 | 2023-08-15 | 溪砾科技(深圳)有限公司 | A method, device, and computer-readable storage medium for identifying drug targets in the untranslated region of mRNA |
| TW202504619A (en) * | 2023-07-20 | 2025-02-01 | 大陸商上海舶望製藥有限公司 | Compositions and methods for inhibiting expression of pd-l1 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5927900A (en) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | Oligonucleotide derivative and its preparation |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| DE3738460A1 (en) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | MODIFIED OLIGONUCLEOTIDS |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| RU2123528C1 (en) * | 1990-11-08 | 1998-12-20 | Чирон Корпорейшн | Method of preparing hcv proteins useful for using in vaccine or immune analysis, asialoglycoprotein (variants), composition for using in vaccine or in immune analysis (variants), method of asialoglycoprotein purification and a method of hcv content decrease or elimination |
| DE69132510T2 (en) | 1990-11-08 | 2001-05-03 | Hybridon, Inc. | CONNECTION OF MULTIPLE REPORTING GROUPS ON SYNTHETIC OLIGONUCLEOTIDS |
| JP2823959B2 (en) | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | Derivatized oligonucleotides with improved uptake and other properties |
| NL9201440A (en) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennary cluster glycosides, their preparation and application. |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| EP0804456B1 (en) | 1994-10-06 | 2002-08-21 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
| US5684142A (en) | 1995-06-07 | 1997-11-04 | Oncor, Inc. | Modified nucleotides for nucleic acid labeling |
| TW520293B (en) | 1995-11-22 | 2003-02-11 | Univ Johns Hopkins Med | Delivery system to enhance cellular uptake of biomolecules |
| JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
| US5770716A (en) | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
| ES2210761T3 (en) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | COMPOSITION AND PROCEDURE TO IMPROVE TRANSPORTATION THROUGH BIOLOGICAL MEMBERS. |
| EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| US6096875A (en) | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| US6335432B1 (en) | 1998-08-07 | 2002-01-01 | Bio-Red Laboratories, Inc. | Structural analogs of amine bases and nucleosides |
| US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
| BRPI0008131B8 (en) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | compound or a salt thereof, oligonucleotide analog, pharmaceutical composition, probe for a gene, initiator to begin amplification, use of an oligonucleotide analog or a pharmacologically acceptable salt thereof, antisense agent, and, antigen agent |
| ATE356824T1 (en) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-RIBO-LNA ANALOGUE |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| WO2005007855A2 (en) | 2003-07-14 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20060276422A1 (en) | 2001-05-18 | 2006-12-07 | Nassim Usman | RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA) |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| DE60334303D1 (en) * | 2002-07-03 | 2010-11-04 | Tasuku Honjo | IMMUNO-POTENTIAL COMPOSITIONS |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| DK2270162T3 (en) | 2003-06-12 | 2019-01-21 | Alnylam Pharmaceuticals Inc | PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING |
| ES2302898T3 (en) | 2003-07-11 | 2008-08-01 | Lbr Medbiotech B.V. | TRANSFER OF GENES TO MUSCLE CELLS MEDIATED BY THE MANOSA-6-PHOSPHATE RECEIVER. |
| CN101084438B (en) * | 2004-10-06 | 2013-12-25 | 梅约医学教育与研究基金会 | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
| PL1810026T3 (en) | 2004-10-06 | 2018-08-31 | Mayo Foundation For Medical Education And Research | B7-H1 and PD-1 in the treatment of renal cell carcinoma |
| US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| DK1907000T4 (en) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Methods and compositions for treating persistent HIV infections by inhibiting the pathway of programmed cell death 1 (PD-1). |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| DE602007009487D1 (en) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGUE |
| EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| DK2170917T3 (en) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituted bicyclic nucleic acid analogs with aminomethylene bridge |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| US9290534B2 (en) | 2008-04-04 | 2016-03-22 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside |
| US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| MX2011005691A (en) | 2008-11-28 | 2011-07-20 | Univ Emory | Methods for the treatment of infections and tumors. |
| MX356367B (en) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function. |
| CN107090437A (en) | 2009-03-06 | 2017-08-25 | 国立大学法人三重大学 | Method for strengthening T cell function |
| CN102459596B (en) * | 2009-05-06 | 2016-09-07 | 库尔纳公司 | Treatment of Lipid Transport and Metabolism Gene-Associated Diseases by Inhibition of Natural Antisense Transcripts Targeting Lipid Transport and Metabolism Genes |
| KR101704988B1 (en) * | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| EP3578657B1 (en) * | 2010-04-06 | 2024-03-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
| US8765708B2 (en) * | 2010-05-18 | 2014-07-01 | Kevin Petrecca | Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas |
| US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| RU2745848C2 (en) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | RNA INTERFERENCE-MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION WITH THE USE OF A SMALL INTERFERING NUCLEIC ACID (siNA) |
| ES2730393T3 (en) | 2010-10-28 | 2019-11-11 | Benitec Biopharma Ltd | HBV treatment |
| RU2013117288A (en) | 2010-12-17 | 2015-01-27 | Эрроухэд Рисерч Корпорейшн | CONTAINING GALACTOSY CLUSTER A TARGETING GROUP FOR miRNA MODULATING FORMKOKINETIC PROPERTIES |
| RU2582235C2 (en) | 2010-12-29 | 2016-04-20 | Ф.Хоффманн-Ля Рош Аг | Low-molecular conjugates for intracellular delivery of nucleic acids |
| SI3505528T1 (en) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulation of hepatitis b virus (hbv) expression |
| PT2726613T (en) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| CN107365339A (en) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | Methods of Synthesizing Functionalized Nucleic Acids |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP2753631A1 (en) | 2011-09-07 | 2014-07-16 | Marina Biotech, Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| WO2013049307A2 (en) | 2011-09-30 | 2013-04-04 | University Of Miami | Enhanced immune memory development by aptamer targeted mtor inhibition of t cells |
| ES2918580T3 (en) * | 2011-10-17 | 2022-07-19 | Io Biotech Aps | PD-L1-based immunotherapy |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| JP2016528873A (en) | 2012-05-16 | 2016-09-23 | ラナ セラピューティクス インコーポレイテッド | Compositions and methods for regulating gene expression |
| EA201492120A1 (en) * | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 EXPRESSION |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| RU2692773C2 (en) | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Identification of patients in need of combined therapy with pd-l1 inhibitor |
| CA2893801A1 (en) * | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| WO2014118272A1 (en) * | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| PL2992098T3 (en) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating hbv and ttr expression |
| MX367083B (en) | 2013-06-27 | 2019-08-05 | Roche Innovation Ct Copenhagen As | Antisense oligomers and conjugates targeting pcsk9. |
| WO2015114146A1 (en) * | 2014-02-03 | 2015-08-06 | Sividon Diagnostics Gmbh | Method for predicting the response to an anti-her2 containing therapy and/or chemotherapy in patients with breast cancer |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| AU2015329974B2 (en) | 2014-10-10 | 2019-06-20 | F. Hoffmann-La Roche Ag | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use |
| WO2016138278A2 (en) | 2015-02-27 | 2016-09-01 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
| WO2017055423A1 (en) * | 2015-10-02 | 2017-04-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugation process |
| WO2017084987A1 (en) | 2015-11-16 | 2017-05-26 | F. Hoffmann-La Roche Ag | GalNAc CLUSTER PHOSPHORAMIDITE |
| WO2017100587A1 (en) | 2015-12-09 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof |
| CA3013683C (en) | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| WO2018215049A1 (en) | 2017-05-23 | 2018-11-29 | F. Hoffmann-La Roche Ag | Process for galnac oligonucleotide conjugates |
-
2017
- 2017-03-14 CA CA3013683A patent/CA3013683C/en active Active
- 2017-03-14 CN CN201780017220.7A patent/CN108779465B/en active Active
- 2017-03-14 PE PE2022000852A patent/PE20230157A1/en unknown
- 2017-03-14 CA CA3120687A patent/CA3120687A1/en active Pending
- 2017-03-14 PE PE2020000807A patent/PE20201499A1/en unknown
- 2017-03-14 KR KR1020187026546A patent/KR102306797B1/en active Active
- 2017-03-14 TW TW111134997A patent/TWI840950B/en active
- 2017-03-14 CN CN202210443059.2A patent/CN114736901B/en active Active
- 2017-03-14 CN CN202111366505.6A patent/CN114085836B/en active Active
- 2017-03-14 CN CN202210442730.1A patent/CN114736900B/en active Active
- 2017-03-14 RS RS20210240A patent/RS61528B1/en unknown
- 2017-03-14 CN CN202210440723.8A patent/CN114717235A/en active Pending
- 2017-03-14 JP JP2018548393A patent/JP6748219B2/en active Active
- 2017-03-14 UA UAA201810179A patent/UA127432C2/en unknown
- 2017-03-14 TW TW106108305A patent/TWI721128B/en active
- 2017-03-14 ES ES17710874T patent/ES2857702T3/en active Active
- 2017-03-14 HU HUE17710874A patent/HUE053172T2/en unknown
- 2017-03-14 RU RU2018134379A patent/RU2747822C2/en active
- 2017-03-14 HR HRP20210315TT patent/HRP20210315T1/en unknown
- 2017-03-14 TW TW113111556A patent/TW202428874A/en unknown
- 2017-03-14 TW TW109135755A patent/TWI790485B/en active
- 2017-03-14 IL IL296483A patent/IL296483B2/en unknown
- 2017-03-14 WO PCT/EP2017/055925 patent/WO2017157899A1/en not_active Ceased
- 2017-03-14 KR KR1020217030513A patent/KR102417646B1/en active Active
- 2017-03-14 PL PL17710874T patent/PL3430141T3/en unknown
- 2017-03-14 US US15/458,800 patent/US20170283496A1/en not_active Abandoned
- 2017-03-14 CR CR20180432A patent/CR20180432A/en unknown
- 2017-03-14 IL IL303077A patent/IL303077B2/en unknown
- 2017-03-14 TW TW109135754A patent/TWI794662B/en active
- 2017-03-14 KR KR1020237031671A patent/KR102805002B1/en active Active
- 2017-03-14 SI SI201730645T patent/SI3430141T1/en unknown
- 2017-03-14 CR CR20200119A patent/CR20200119A/en unknown
- 2017-03-14 EP EP17710874.3A patent/EP3430141B1/en active Active
- 2017-03-14 PT PT177108743T patent/PT3430141T/en unknown
- 2017-03-14 EP EP20201780.2A patent/EP3786297A1/en active Pending
- 2017-03-14 PE PE2018001567A patent/PE20181892A1/en unknown
- 2017-03-14 KR KR1020227022628A patent/KR102580776B1/en active Active
- 2017-03-14 MX MX2018010830A patent/MX2018010830A/en unknown
- 2017-03-14 IL IL317818A patent/IL317818A/en unknown
- 2017-03-14 AR ARP170100626A patent/AR108038A1/en unknown
- 2017-03-14 DK DK17710874.3T patent/DK3430141T3/en active
- 2017-03-14 LT LTEP17710874.3T patent/LT3430141T/en unknown
- 2017-03-14 SG SG11201807854SA patent/SG11201807854SA/en unknown
- 2017-03-14 KR KR1020257014623A patent/KR20250065735A/en active Pending
- 2017-03-14 AU AU2017235278A patent/AU2017235278C1/en active Active
- 2017-03-14 MY MYPI2018703228A patent/MY194912A/en unknown
-
2018
- 2018-07-24 IL IL260759A patent/IL260759B/en unknown
- 2018-07-26 CO CONC2018/0007761A patent/CO2018007761A2/en unknown
- 2018-09-07 MX MX2022012221A patent/MX2022012221A/en unknown
- 2018-09-07 CL CL2018002570A patent/CL2018002570A1/en unknown
- 2018-09-12 PH PH12018501964A patent/PH12018501964A1/en unknown
-
2019
- 2019-10-25 US US16/664,749 patent/US10745480B2/en active Active
-
2020
- 2020-03-31 CL CL2020000865A patent/CL2020000865A1/en unknown
- 2020-04-02 US US16/839,025 patent/US10829555B2/en active Active
- 2020-04-17 AR ARP200101090A patent/AR118719A2/en unknown
- 2020-04-28 CL CL2020001126A patent/CL2020001126A1/en unknown
- 2020-04-28 CL CL2020001127A patent/CL2020001127A1/en unknown
- 2020-06-22 JP JP2020106728A patent/JP7002603B2/en active Active
- 2020-08-21 US US17/000,203 patent/US11466081B2/en active Active
-
2021
- 2021-09-20 AU AU2021236439A patent/AU2021236439B2/en active Active
- 2021-12-27 JP JP2021212541A patent/JP7447073B2/en active Active
-
2022
- 2022-02-01 IL IL290294A patent/IL290294B2/en unknown
- 2022-04-13 AU AU2022202479A patent/AU2022202479B2/en active Active
- 2022-10-07 US US18/045,109 patent/US12552862B2/en active Active
-
2024
- 2024-01-04 JP JP2024000251A patent/JP7791222B2/en active Active
- 2024-05-29 AU AU2024203581A patent/AU2024203581B2/en active Active
-
2025
- 2025-12-11 JP JP2025245488A patent/JP2026075623A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210315T1 (en) | Oligonucleotides for reduction of pd-l1 expression | |
| US20230302146A1 (en) | Hybrid carriers for nucleic acid cargo | |
| TWI680767B (en) | Compounds and methods for enhanced cellular uptake | |
| TWI739740B (en) | Rna containing composition for treatment of tumor diseases | |
| IL300119A (en) | Oligonucleotides for inducing paternal ube3a expression | |
| JP2019512498A5 (en) | ||
| JP7366057B2 (en) | Synthetic RIG-I-like receptor agonists | |
| JP2018523668A5 (en) | ||
| JP2018536689A5 (en) | ||
| WO2019140140A1 (en) | Rna-nanostructured double robots and methods of use thereof | |
| EA008741B1 (en) | C-class oligonucleotide analogs with enhanced immunostimulatory potency | |
| TW202600825A (en) | Compositions and methods for inhibiting gene expression of lpa | |
| WO2009109665A4 (en) | Pharmaceutical compositions for treatment of microrna related diseases | |
| US10041076B2 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
| US20210269797A1 (en) | Methods and compositions for targeting pd-l1 | |
| EP3758712B1 (en) | Cpg amphiphiles and uses thereof | |
| US20230310594A1 (en) | Methods of treating a latent hiv-1 infection using non-coding deoxyribonucleic acids | |
| CN115702006A (en) | Conjugate group and conjugate thereof | |
| KR20090021295A (en) | Bioactive Purified HspE7 Composition | |
| EP4719437A1 (en) | Connector modified synthetic rig-i agonists and methods of using the same | |
| WO2013027063A1 (en) | Chemically programmable immunity | |
| CN101503437B (en) | Nucleic acid molecule SI-CYPJ-4 and use thereof in anti-cancer medicine preparation | |
| HK40045177B (en) | Cpg amphiphiles and uses thereof | |
| HK40045177A (en) | Cpg amphiphiles and uses thereof | |
| NZ753783B2 (en) | Modified oligonucleotides for treatment of polycystic kidney disease |